Explore

Companies

Drugs

/

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Oncology/Germ Cell Tumor

Germ Cell Tumor

13

Pipeline Programs↗

16

Active Trials↗

9

Companies Involved↗

Germ Cell Tumor is an emerging landscape with 13 programs across 9 companies. 7 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

46/100

Pipeline Velocity

19/100

Mech. Concentration

50/100

Completion Rate

72/100

Attrition Rate

19/100

Pipeline

Programs by Phase

Preclinical1

Axumin PET Scan

University of Texas Southwestern Medical Center

Phase 12

Dbc-664

Duboce Biopharmaceuticals, Inc.

Sodium Thiosulfate Anhydrous

City of Hope Medical Center

Phase 23

Carboplatin/etoposide

Gemin X

Ifosfamide/cisplatin/etoposide

Beijing Tiantan Hospital

Teniposide

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 37

Carboplatin

Avyxa

Filgrastim

Eastern Cooperative Oncology Group

Bleomycin

Bristol-Myers Squibb

Etoposide

Avyxa

Bleomycin Sulfate

Bristol-Myers Squibb

Approved

No programs

Analysis

Modality Breakdown

91%

Small molecule

10 of 11 classified programs — the dominant modality here.

Small molecule leads; the ring shows all 11 classified programs, each share of the total. Modality classified for 92% of 13 pipeline programs.

Analysis

Trial Status

80

clinical trials

Completed39 · 49%

Recruiting14 · 18%

Terminated13 · 16%

Unknown status10 · 13%

Active, not recruiting2 · 3%

Withdrawn2 · 3%

Clinical Trials

Trial Activity

80 trials

Phase 3 Accelerated BEP: A Randomised Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours

Recruiting·UUniversity of Sydney·Phase 3·NCT02582697·500 enrolled

Sentinel Node Identification Using Gamma Detection and Near-Infrared Fluorescence in Testicular Malignancies

Recruiting·NN.N. Petrov National Medical Research Center of Oncology·N/A·NCT07777887·60 enrolled

A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors

Recruiting·Children's Oncology Group·Phase 3·NCT03067181·1,780 enrolled

A Phase 1a/1b Open Label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Activity of DBC-664 in Adult Patients With Locally Advanced or Metastatic Solid Tumors

Recruiting·DDuboce Biopharmaceuticals, Inc.·Phase 1·NCT07705035·210 enrolled

Phase II Trial of Serum Micro RNA-371 in Detecting Active Germ Cell Tumors in Patients With Suspected Regional Disease - (MAGESTIC Trial: MiRNA in Detecting Active Germ Cell Tumors in Early Suspected and MetastaTIC Disease Trial)

Recruiting·UUniversity of Southern California·N/A·NCT06060873·418 enrolled

A Single-arm, Phase II Clinical Trial of ASPIRin to prEvent Venous Thromboembolism in Patients With Advanced Germ Cell Tumors Receiving Chemotherapy

Recruiting·WWake Forest University Health Sciences·Phase 2·NCT06866964·35 enrolled

The Efficacy of WVI in Patients With Localized Basal Ganglia Intracranial Germ Cell Tumors

Recruiting·—·Phase 2·NCT05124951·150 enrolled

TC or BEP in Treating Patients With Malignant Ovarian Germ Cell Tumors

Recruiting·—·Phase 3·NCT02429687·129 enrolled

Thromboprophylaxis in Good and Intermediate Prognosis Advanced Germ Cell Tumors

Recruiting·GGustave Roussy, Cancer Campus, Grand Paris·Phase 3·NCT05874063·387 enrolled

Treatment of Newly Diagnosed Central Malignant Germ Cell Tumor People With Teniposide Injection Combined With Cisplatin.

Recruiting·—·Phase 2·NCT07188441·40 enrolled

High-dose Chemotherapy as Second-line Drug Therapy for Relapsed Germ Cell Tumors

Recruiting·NN.N. Petrov National Medical Research Center of Oncology·Phase 2·NCT06418789·25 enrolled

Evaluation of Bile Acid Concentrations and Their Signaling as Markers of Testicular Tumorigenesis and Germ Cell Tumor Chemosensitivity

Recruiting·UUniversity Hospital, Clermont-Ferrand·N/A·NCT07463508·20 enrolled

Paclitaxel/Ifosfamide/Cisplatin Chemotherapy for High Risk Pediatric Germ Cell Tumor

Recruiting·YYonsei University·Phase 2·NCT05455918·42 enrolled

Testing the Addition of Pedmark to Cisplatin Chemotherapy for Reducing Drug-Induced Ear Damage in Men With Stage II-III Metastatic Testicular Germ Cell Tumors

Recruiting·—·Phase 1·NCT07218913·44 enrolled

A Single-arm, Phase II Study of Durvalumab (MEDI4736) and Tremelimumab for Relapsed/Refractory Germ Cell Tumors

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT03158064·30 enrolled

Page 1 of 6

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)